BMS-986506 / BMS - LARVOL DELTA

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (clinicaltrials.gov) - P1 | N=125 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

First-in-human • New P1 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor